Mieloma múltiple: clínica, paraclínica y principales esquemas de tratamiento Hospital de San José de Bogotá DC. 2003 a 2010

Autores:: Abello Polo, Virginia
Figueroa Emiliani, Jair
Villamizar Gómez, Francy Licet

Tipo de recurso:: Article of journal

Fecha de publicación:: 2012

Institución:: Fundación Universitaria de Ciencias de la Salud - FUCS

Repositorio:: Repositorio Digital Institucional ReDi

Idioma:: spa

id	FUCS2_af943ee594ef7d4f2123408391a3e057
oai_identifier_str	oai:repositorio.fucsalud.edu.co:001/2825
network_acronym_str	FUCS2
network_name_str	Repositorio Digital Institucional ReDi
repository_id_str
dc.title.spa.fl_str_mv	Mieloma múltiple: clínica, paraclínica y principales esquemas de tratamiento Hospital de San José de Bogotá DC. 2003 a 2010
dc.title.translated.eng.fl_str_mv	Multiple Myeloma: clinical and laboratory manifestations and main treatment regimens Hospital de San José de Bogotá DC. 2003 to 2010
title	Mieloma múltiple: clínica, paraclínica y principales esquemas de tratamiento Hospital de San José de Bogotá DC. 2003 a 2010
spellingShingle	Mieloma múltiple: clínica, paraclínica y principales esquemas de tratamiento Hospital de San José de Bogotá DC. 2003 a 2010 mieloma múltiple tratamiento trasplante autólogo de células madres hematopoyéticas neoplasia de células plasmáticas recaída multiple myeloma treatment autologous hematopoietic stem cell transplantation cancer of the plasma cells relapse
title_short	Mieloma múltiple: clínica, paraclínica y principales esquemas de tratamiento Hospital de San José de Bogotá DC. 2003 a 2010
title_full	Mieloma múltiple: clínica, paraclínica y principales esquemas de tratamiento Hospital de San José de Bogotá DC. 2003 a 2010
title_fullStr	Mieloma múltiple: clínica, paraclínica y principales esquemas de tratamiento Hospital de San José de Bogotá DC. 2003 a 2010
title_full_unstemmed	Mieloma múltiple: clínica, paraclínica y principales esquemas de tratamiento Hospital de San José de Bogotá DC. 2003 a 2010
title_sort	Mieloma múltiple: clínica, paraclínica y principales esquemas de tratamiento Hospital de San José de Bogotá DC. 2003 a 2010
dc.creator.fl_str_mv	Abello Polo, Virginia Figueroa Emiliani, Jair Villamizar Gómez, Francy Licet
dc.contributor.author.spa.fl_str_mv	Abello Polo, Virginia Figueroa Emiliani, Jair
dc.contributor.author.none.fl_str_mv	Villamizar Gómez, Francy Licet
dc.subject.spa.fl_str_mv	mieloma múltiple tratamiento trasplante autólogo de células madres hematopoyéticas neoplasia de células plasmáticas recaída
topic	mieloma múltiple tratamiento trasplante autólogo de células madres hematopoyéticas neoplasia de células plasmáticas recaída multiple myeloma treatment autologous hematopoietic stem cell transplantation cancer of the plasma cells relapse
dc.subject.eng.fl_str_mv	multiple myeloma treatment autologous hematopoietic stem cell transplantation cancer of the plasma cells relapse
publishDate	2012
dc.date.accessioned.none.fl_str_mv	2012-06-01 00:00:00 2022-06-29T19:36:52Z
dc.date.issued.none.fl_str_mv	2012-06-01
dc.date.available.none.fl_str_mv	2012-06-01 00:00:00 2022-06-29T19:36:52Z
dc.type.spa.fl_str_mv	Artículo de revista
dc.type.eng.fl_str_mv	Journal article
dc.type.coar.spa.fl_str_mv	http://purl.org/coar/resource_type/c_6501 http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.driver.spa.fl_str_mv	info:eu-repo/semantics/article
dc.type.version.spa.fl_str_mv	info:eu-repo/semantics/publishedVersion
dc.type.content.spa.fl_str_mv	Text
dc.type.redcol.spa.fl_str_mv	http://purl.org/redcol/resource_type/ART
dc.type.coarversion.spa.fl_str_mv	http://purl.org/coar/version/c_970fb48d4fbd8a85
format	http://purl.org/coar/resource_type/c_6501
status_str	publishedVersion
dc.identifier.doi.none.fl_str_mv	10.31260/RepertMedCir.v21.n2.2012.804
dc.identifier.issn.none.fl_str_mv	0121-7372
dc.identifier.uri.none.fl_str_mv	https://repositorio.fucsalud.edu.co/handle/001/2825
dc.identifier.eissn.none.fl_str_mv	2462-991X
dc.identifier.url.none.fl_str_mv	https://doi.org/10.31260/RepertMedCir.v21.n2.2012.804
identifier_str_mv	10.31260/RepertMedCir.v21.n2.2012.804 0121-7372 2462-991X
url	https://repositorio.fucsalud.edu.co/handle/001/2825 https://doi.org/10.31260/RepertMedCir.v21.n2.2012.804
dc.language.iso.spa.fl_str_mv	spa
language	spa
dc.relation.references.spa.fl_str_mv	Ries LAG, Eisner MP, Kosary C, et al. SEER Cancer Statistics Review, 1975- 2001. Betbesda, MD, National CancerInstitute. 2004. 2. Blade J, Kyle RA. Multiple myeloma in young patients: clinical presentation and treatment approach. Leuk Lymphoma. 1998 Aug;30(5-6):493-50I. 3. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225. 4. Kyle RA, Gertz M, Witzig TE, et al. Review of 1027 patients with newly diag nosed multiple myeloma. Mayo Clin Proc. 2003;78:21. 5. Ferlay J, Shin H. Bray F, Fomrnn D, Mathers C PD. Estimates of worldwide bur den of cancer in 2008: GLOBOCAN 2008. Int J Clin Pract. 20l 0;127:2893-917. 6. Instituto Nacional de Cancerología. Anuario Estadístico. 2009;7. 7. Smith A, Wisloff F, Samson D. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol. 2006;132:410. 8. Rajkumar SV, Dispenzieri A, Kyle RA. Monoclonal gammopathy of under termined significance, Waldenstrom macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatrnent. Mayo Clin Proc. 2006;8 I :693. 9. Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R, et al. Management of newly diagnosed symptomalic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc. 2009 Dec;84(12):1095-IJ0. 10. Greipp PR, San MJ, Durie BG, et al. lntemational staging system far multiple myeloma. J Clin Oncol. 2005;23:3412. 11. Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurren! genomic aberrations in myeloma. Blood. 2003;101:4569. 12. Durie BG, Harousseau JL, Miguel JS, et al. International unifarm response crite ria for multiple myeloma. Leukemia. 2006;20:1467. 13. Munshi NC. Plasma cell disorders: an historical perspective. Hematology. 2008;2008(297). 14. Anderson KC, Faber E, Samio G, Alsina M, Huff CA, Stockerl-Goldstein KE, et al. NCCN Clinical Practice Guidelines in Oncology. National Compreheosive Cancer Network. 2011;1.201I:1-53. 15. Atta! M, Harousseau JL, Stoppa AM, Sotto J, Fuzibet J, Rossi JF, et al. A pro spective, randomized tria! of autologous bone marrow transplantation and che motherapy in multiple myeloma. lntergroupe Francais du Myélome. N Engl J Med. l996;335(2):91-7. 16. Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol. 2011;8(8):479-81. 17. Palumbo A, Triolo S, Argentino C, Bringhen S, Dominietto A, Rus C, et al. Dose-intensive melphalan with stem cell support (MELI00) is superior to stan dard treatrnent in elderly myeloma patients. Blood. 1999;94(4):1248-53. 18. Kyle RA, Themeau TM. Rajkumar SV, el al. Incidence of multiple myeloma in Olmsled County, Minnesota: Trend over 6 decades. Cancer. 2004;101:2667. 19. Kapoor P, Rajkumar SV. Update on risk stratification aod treatment of newly diagnosed multiple myeloma. Int J Hemalol. 2011;JO:1007. 20. Barlogie B, Alexanian R, Dicke KA, el al. High-dose chemoradiotherapy and autologous bone marrow transplantation far resistant multiple myeloma. Br J Haematol. l 987;66(1):55-62. 21. Alexanian R, Weber D, Giralt S, Delasalle K, Smith T, et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant. 2001;27(10):1037-43. 22. Singhal S, Mehla J, Desikan R, el al. Antitumor activity of thalidomide in refrac tory multiple myeloma. N Engl J Med. 1999;341:1565-71. 23. Cavo M, Zamagni E, Tasi P, Taccetti P, Cellini C, Canning C. Superiority of thalidomide and dexamethasone over vincristine - doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation far mul tiple myeloma. Blood. 2005;106:35-9. 24. Rajkumar SV. Multiple myeloma: the death of VAD as initial therapy. Blood. 2005;106:2-3.
dc.relation.bitstream.none.fl_str_mv	https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/804/839
dc.relation.citationedition.spa.fl_str_mv	Núm. 2 , Año 2012 : Abril – Junio
dc.relation.citationendpage.none.fl_str_mv	114
dc.relation.citationissue.spa.fl_str_mv	2
dc.relation.citationstartpage.none.fl_str_mv	108
dc.relation.citationvolume.spa.fl_str_mv	21
dc.relation.ispartofjournal.spa.fl_str_mv	Revista Repertorio de Medicina y Cirugía
dc.rights.accessrights.spa.fl_str_mv	info:eu-repo/semantics/openAccess
dc.rights.uri.spa.fl_str_mv	https://creativecommons.org/licenses/by-nc-sa/4.0/
dc.rights.coar.spa.fl_str_mv	http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv	openAccess
rights_invalid_str_mv	https://creativecommons.org/licenses/by-nc-sa/4.0/ http://purl.org/coar/access_right/c_abf2
dc.format.mimetype.spa.fl_str_mv	application/pdf
dc.publisher.spa.fl_str_mv	Sociedad de Cirugía de Bogotá, Hospital de San José y Fundación Universitaria de Ciencias de la Salud
dc.source.spa.fl_str_mv	https://revistas.fucsalud.edu.co/index.php/repertorio/article/view/804
institution	Fundación Universitaria de Ciencias de la Salud - FUCS
bitstream.url.fl_str_mv	https://repositorio.fucsalud.edu.co/bitstreams/ff17ddc3-36c3-489e-9149-8236cbfb6e18/download
bitstream.checksum.fl_str_mv	4bca4f23068ba7af8a8020380126ab80
bitstream.checksumAlgorithm.fl_str_mv	MD5
repository.name.fl_str_mv	Repositorio Digital de la Fundación Universitaria de Ciencias de la Salud
repository.mail.fl_str_mv	redi@fucsalud.edu.co
_version_	1811575299937140736
spelling	Abello Polo, Virginia209c84f71d80e0fc858cea50ac1e05db500Figueroa Emiliani, Jair762d2b657fcebb36821ca5a503acad6d300Villamizar Gómez, Francy Licetvirtual::37-12012-06-01 00:00:002022-06-29T19:36:52Z2012-06-012012-06-01 00:00:002022-06-29T19:36:52ZSociedad de Cirugía de Bogotá, Hospital de San José y Fundación Universitaria de Ciencias de la Saludhttps://revistas.fucsalud.edu.co/index.php/repertorio/article/view/804mieloma múltipletratamientotrasplante autólogo de células madres hematopoyéticasneoplasia de células plasmáticasrecaídamultiple myelomatreatmentautologous hematopoietic stem cell transplantationcancer of the plasma cellsrelapseMieloma múltiple: clínica, paraclínica y principales esquemas de tratamiento Hospital de San José de Bogotá DC. 2003 a 2010Multiple Myeloma: clinical and laboratory manifestations and main treatment regimens Hospital de San José de Bogotá DC. 2003 to 2010application/pdfArtículo de revistaJournal articlehttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionTexthttp://purl.org/redcol/resource_type/ARThttp://purl.org/coar/version/c_970fb48d4fbd8a8510.31260/RepertMedCir.v21.n2.2012.8040121-7372https://repositorio.fucsalud.edu.co/handle/001/28252462-991Xhttps://doi.org/10.31260/RepertMedCir.v21.n2.2012.804spaRies LAG, Eisner MP, Kosary C, et al. SEER Cancer Statistics Review, 1975- 2001. Betbesda, MD, National CancerInstitute. 2004. 2. Blade J, Kyle RA. Multiple myeloma in young patients: clinical presentation and treatment approach. Leuk Lymphoma. 1998 Aug;30(5-6):493-50I. 3. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225. 4. Kyle RA, Gertz M, Witzig TE, et al. Review of 1027 patients with newly diag nosed multiple myeloma. Mayo Clin Proc. 2003;78:21. 5. Ferlay J, Shin H. Bray F, Fomrnn D, Mathers C PD. Estimates of worldwide bur den of cancer in 2008: GLOBOCAN 2008. Int J Clin Pract. 20l 0;127:2893-917. 6. Instituto Nacional de Cancerología. Anuario Estadístico. 2009;7. 7. Smith A, Wisloff F, Samson D. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol. 2006;132:410. 8. Rajkumar SV, Dispenzieri A, Kyle RA. Monoclonal gammopathy of under termined significance, Waldenstrom macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatrnent. Mayo Clin Proc. 2006;8 I :693. 9. Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R, et al. Management of newly diagnosed symptomalic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc. 2009 Dec;84(12):1095-IJ0. 10. Greipp PR, San MJ, Durie BG, et al. lntemational staging system far multiple myeloma. J Clin Oncol. 2005;23:3412. 11. Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurren! genomic aberrations in myeloma. Blood. 2003;101:4569. 12. Durie BG, Harousseau JL, Miguel JS, et al. International unifarm response crite ria for multiple myeloma. Leukemia. 2006;20:1467. 13. Munshi NC. Plasma cell disorders: an historical perspective. Hematology. 2008;2008(297). 14. Anderson KC, Faber E, Samio G, Alsina M, Huff CA, Stockerl-Goldstein KE, et al. NCCN Clinical Practice Guidelines in Oncology. National Compreheosive Cancer Network. 2011;1.201I:1-53. 15. Atta! M, Harousseau JL, Stoppa AM, Sotto J, Fuzibet J, Rossi JF, et al. A pro spective, randomized tria! of autologous bone marrow transplantation and che motherapy in multiple myeloma. lntergroupe Francais du Myélome. N Engl J Med. l996;335(2):91-7. 16. Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol. 2011;8(8):479-81. 17. Palumbo A, Triolo S, Argentino C, Bringhen S, Dominietto A, Rus C, et al. Dose-intensive melphalan with stem cell support (MELI00) is superior to stan dard treatrnent in elderly myeloma patients. Blood. 1999;94(4):1248-53. 18. Kyle RA, Themeau TM. Rajkumar SV, el al. Incidence of multiple myeloma in Olmsled County, Minnesota: Trend over 6 decades. Cancer. 2004;101:2667. 19. Kapoor P, Rajkumar SV. Update on risk stratification aod treatment of newly diagnosed multiple myeloma. Int J Hemalol. 2011;JO:1007. 20. Barlogie B, Alexanian R, Dicke KA, el al. High-dose chemoradiotherapy and autologous bone marrow transplantation far resistant multiple myeloma. Br J Haematol. l 987;66(1):55-62. 21. Alexanian R, Weber D, Giralt S, Delasalle K, Smith T, et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant. 2001;27(10):1037-43. 22. Singhal S, Mehla J, Desikan R, el al. Antitumor activity of thalidomide in refrac tory multiple myeloma. N Engl J Med. 1999;341:1565-71. 23. Cavo M, Zamagni E, Tasi P, Taccetti P, Cellini C, Canning C. Superiority of thalidomide and dexamethasone over vincristine - doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation far mul tiple myeloma. Blood. 2005;106:35-9. 24. Rajkumar SV. Multiple myeloma: the death of VAD as initial therapy. Blood. 2005;106:2-3.https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/804/839Núm. 2 , Año 2012 : Abril – Junio114210821Revista Repertorio de Medicina y Cirugíainfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/4.0/http://purl.org/coar/access_right/c_abf2Publication89867781-8b73-4edb-adc3-85bacc6d7d3dvirtual::37-189867781-8b73-4edb-adc3-85bacc6d7d3dvirtual::37-10000-0002-1875-114Xvirtual::37-1https://scienti.minciencias.gov.co/cvlac/visualizador/generarCurriculoCv.do?cod_rh=0000498319virtual::37-1OREORE.xmltext/xml2823https://repositorio.fucsalud.edu.co/bitstreams/ff17ddc3-36c3-489e-9149-8236cbfb6e18/download4bca4f23068ba7af8a8020380126ab80MD51001/2825oai:repositorio.fucsalud.edu.co:001/28252024-06-14 10:48:29.611https://creativecommons.org/licenses/by-nc-sa/4.0/metadata.onlyhttps://repositorio.fucsalud.edu.coRepositorio Digital de la Fundación Universitaria de Ciencias de la Saludredi@fucsalud.edu.co

Mieloma múltiple: clínica, paraclínica y principales esquemas de tratamiento Hospital de San José de Bogotá DC. 2003 a 2010

Publicaciones similares